RT Journal Article
SR Electronic
T1 Sample Size Calculations for Variant Surveillance in the Presence of Biological and Systematic Biases
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.30.21268453
DO 10.1101/2021.12.30.21268453
A1 Shirlee Wohl
A1 Elizabeth C. Lee
A1 Bethany L. DiPrete
A1 Justin Lessler
YR 2022
UL http://medrxiv.org/content/early/2022/01/01/2021.12.30.21268453.abstract
AB As demonstrated during the SARS-CoV-2 pandemic, detecting and tracking the emergence and spread of pathogen variants is an important component of monitoring infectious disease outbreaks. Pathogen genome sequencing has emerged as the primary tool for variant characterization, so it is important to consider the number of sequences needed when designing surveillance programs or studies, both to ensure accurate conclusions and to optimize use of limited resources. However, current approaches to calculating sample size for variant monitoring often do not account for the biological and logistical processes that can bias which infections are detected and which samples are ultimately selected for sequencing. In this manuscript, we introduce a framework that models the full process from infection detection to variant characterization and demonstrate how to use this framework to calculate appropriate sample sizes for sequencing-based surveillance studies. We consider both cross-sectional and continuous sampling, and we have implemented our method in a publicly available tool that allows users to estimate necessary sample sizes given a specific aim (e.g., variant detection or measuring variant prevalence) and sampling method. Our framework is designed to be easy to use, while also flexible enough to be adapted to other pathogens and surveillance scenarios.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding was provided by Bill and Melinda Gates Foundation INV-025321 (S.W.) and OPP1195157 (S.W. and J.L.).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesCode to produce figures is available at: https://github.com/HopkinsIDD/VOCsamplesize. https://github.com/HopkinsIDD/VOCsamplesize